Cirrhosis and chronic liver failure: Part II. Complications and treatment

American Family Physician

Volumn 74, Issue 5, 2006, Pages

  Heidelbaugh, Joel J ^a,b,c   Sherbondy, Maryann ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Ypsilanti (Mich) Health Center   (United States)

^c Ypsilanti Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; COTRIMOXAZOLE; DIURETIC AGENT; DOPAMINE; ENEMA; FLUMAZENIL; FUROSEMIDE; ISOSORBIDE MONONITRATE; LACTULOSE; MIDODRINE; NEOMYCIN; NORFLOXACIN; OCTREOTIDE; OFLOXACIN; PROPRANOLOL; SPIRONOLACTONE;

ASCITES; BACTERIAL PERITONITIS; BLEEDING; ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; PARACENTESIS; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; REVIEW; SCLEROTHERAPY; SODIUM RESTRICTION; VARICOSIS;

ASCITES; CHRONIC DISEASE; DIET, SODIUM-RESTRICTED; DIURETICS; HEPATORENAL SYNDROME; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; PROGNOSIS;

EID: 33748579892     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure. Part I: Diagnosis and evaluation. Am Fam Physician 2006;74:756-62.
2. Runyon BA. Ascites and spontaneous bacterial peritonitis. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 7th ed. Philadelphia, Pa.: Saunders, 2002:1517-42.
3. Runyon BA, and the Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of adult patients with ascites due to cirrhosis. Hepatology 2004;39:841-56.
4. Hoefs JC. Serum protein concentration and portal pressure determine the ascitic fluid protein concentration in patients with chronic liver disease. J Lab Clin Med 1983;102:260-73.
5. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992;117:215-20.
6. Lucey MR. Diseases of the peritoneum, mesentery, and omentum. In: Goldman L, Bennett JC, eds. Cecil Textbook of Medicine. 21st ed. Philadelphia, Pa.: Saunders, 2000:759-63.
7. Fitz JG. Hepatic encephalopathy, hepatopulmonary syndromes, hepatorenal syndrome, coagulopathy, and endocrine complications of liver disease. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 7th ed. Philadelphia, Pa.: Saunders, 2002:1543-54.
8. Strauss E, Tramote R, Silva EP, Caly WR, Honain NZ, Maffei RA, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992;39:542-5.
9. Jalan R, Hayes PC. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology. Gut 2000;46(suppl 3-4):III1-III15.
10. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-7.
11. Cordoba J, Lopez-Hellin J, Planas M, Sabin P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004;41:38-43.
12. Naylor CD, O'Rourke K, Detsky AS, Baker JP. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology 1989;97:1033-42.
13. Blei AT, Cordoba J, and the Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968-76.
14. Cales P, Zabotto B, Meskens C, Caucanas JP, Vinel JP, Desmorat H, et al. Gastroesophageal endoscopic features in cirrhosis. Observer variability, interassociations, and relationship to hepatic dysfunction. Gastroenterology 1990;98:156-62.
15. Garcia-Pagan JC, Morillas R, Banares R, Albillos A, Villanueva C, Vila C, et al., for the Spanish Variceal Bleeding Study Group. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology 2003;37:1260-6.
16. Jutabha R, Jensen DM, Martin P, Savides T, Han SH, Gornbein J. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology 2005;128:870-81.
17. Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004;40:629-35.
18. De Franchis R, Primignani M. Why do varices bleed? Gastroenterol Clin North Am 1992;21:85-101.
19. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004;40:652-9.
20. Friedman S. Alcoholic liver disease, cirrhosis, and its major sequelae. In: Goldman L, Bennett JC, eds. Cecil Textbook of Medicine. 21st ed. Philadelphia, Pa.: Saunders, 2000:804-12.
21. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-36.
22. Gines P, Torre A, Terra C, Guevara M. Review article: pharmacological treatment of hepatorenal syndrome. Aliment Pharmacol Ther 2004;20(suppl 3):57-62.
23. Better OS. Renal and cardiovascular dysfunction in liver disease. Kidney Int 1986;29:598-607.
24. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-76.
25. Moller S, Henriksen JH. Review article: pathogenesis and pathophysiology of hepatorenal syndrome - is there scope for prevention? Aliment Pharmacol Ther 2004;20(suppl 3):31-41.
26. United Network for Organ Sharing. Data. Accessed May 12, 2006, at: http://www.unos.org/data/.
27. Steinman TI, Becker BN, Frost AE, Olthoff KM, Smart FW, Suki WN, et al., for the Clinical Practice Committee, American Society of Transplantation. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation 2001;71:1189-204.
28. Dove L, Brown R. The emerging role of gastrointestinal organ transplantation. Clin Fam Pract 2004;6:775-91.
29. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al., for the United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-6.
30. Consensus statement on indications for liver transplantation: Paris June 22-23, 1993. Hepatology 1994;20(1 pt 2):63S-68S.
31. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keefe EB, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Transplantation 1998;66:956-62.
32. Davern TJ, Scharschmidt BF. Biochemical liver tests. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 7th ed. Philadelphia, Pa.: Saunders, 2002:1236.
33. Mansour A, Watson W, Shayani V, Pickleman J. Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery 1997;122:730-5.
34. Lake JR. Evaluation and management of prospective liver transplant candidates. In: Norman DJ, Turka LA, eds. Primer on Transplantation. 2nd ed. Mt. Laurel, N.J.: American Society of Transplantation, 2001:523-8.